Related Experiment Video
Updated: Oct 18, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Molecular Dynamics Simulations Identify Tractable Lead-like Phenyl-Piperazine Scaffolds as eIF4A1 ATP-competitive
Derek J Essegian1,2, Tyler A Cunningham1,2, Christopher J Zerio3
1Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida 33136, United States.
Abstract:
eIF4A1 is an ATP-dependent RNA helicase whose overexpression and activity have been tightly linked to oncogenesis in a number of malignancies. An understanding of the complex kinetics and conformational changes of this translational enzyme is necessary to map out all targetable binding sites and develop novel, chemically tractable inhibitors. We herein present a comprehensive quantitative analysis of eIF4A1 conformational changes using protein-ligand docking, homology modeling, and extended molecular dynamics simulations. Through this, we report the discovery of a novel, biochemically active phenyl-piperazine pharmacophore, which is predicted to target the ATP-binding site and may serve as the starting point for medicinal chemistry optimization efforts. This is the first such report of an ATP-competitive inhibitor for eiF4A1, which is predicted to bind in the nucleotide cleft. Our novel interdisciplinary pipeline serves as a framework for future drug discovery efforts for targeting eiF4A1 and other proteins with complex kinetics.
Insights
Researchers identified a novel phenyl-piperazine compound targeting the ATP-binding site of eukaryotic initiation factor 4A1 (eIF4A1), a key protein in cancer development. This discovery offers a new avenue for developing targeted cancer therapies.
Area of Science:
- Biochemistry and Molecular Biology
- Structural Biology
- Drug Discovery
Background:
- Eukaryotic initiation factor 4A1 (eIF4A1) is an ATP-dependent RNA helicase implicated in oncogenesis.
- Understanding eIF4A1's complex kinetics and conformational changes is crucial for developing targeted inhibitors.
Purpose of the Study:
- To quantitatively analyze eIF4A1 conformational changes.
- To discover novel, chemically tractable inhibitors targeting eIF4A1.
Main Methods:
- Protein-ligand docking
- Homology modeling
- Extended molecular dynamics simulations
Main Results:
- Discovery of a novel phenyl-piperazine pharmacophore.
- Predicted binding to the ATP-binding site of eIF4A1.
- Identification of an ATP-competitive inhibitor targeting the nucleotide cleft.
Conclusions:
- The identified pharmacophore is the first reported ATP-competitive inhibitor for eIF4A1.
- The interdisciplinary pipeline provides a framework for future drug discovery targeting eIF4A1 and similar proteins.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015